Physician profile
Margo E Waters
NPI 1639680366
$3,032.02
in general payments reported to CMS, 2019-2025
20 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.83 · 2022: $255 · 2023: $420 · 2024: $1,165 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,594 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,594.05 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,045.05 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $303.65 | 2024-2025 | Voquezna |
| Pfizer INC. | $299.93 | 2021-2025 | |
| Janssen Biotech, INC. | $186.41 | 2024-2025 | Tremfya |
| Ardelyx, INC. | $180.11 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.45 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $157.88 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $111.17 | 2021-2023 | |
| Daiichi Sankyo INC. | $92.01 | 2022-2023 | Injectafer |
| Gilead Sciences, INC. | $74.28 | 2023-2024 | |
| Ironwood Pharmaceuticals, INC | $59.93 | 2023-2024 | Linzess |
| Aimmune Therapeutics, INC. | $58.89 | 2025 | Zenpep, Vowst |
| Abbott Laboratories | $44.65 | 2023 | Amplatzer Amulet |
| Amgen INC. | $38.76 | 2021-2023 | Otezla, Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.79 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $24.05 | 2021-2022 | |
| Medtronic, INC. | $18.88 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.08 | 2023 | Onpattro |
| Takeda Pharmaceuticals U.S.A., INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margo Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.